NewsDialy
Drugmakers and venture capital firms are returning their focus to brittle bone treatments, driven by a recent change in drug approval rules.
Osteoporosis is a condition that thins and weakens bones, making them prone to fracture. This regulatory update has made it easier for companies to bring new therapies to market, reversing years of industry disinterest.
Why the industry stepped back For decades, major pharmaceutical companies treated bone density as a priority. Eli Lilly, Merck, Novartis, and GSK all developed drugs intended to prevent bone weakening.
However, patient adoption stalled. The medications required cumbersome administration schedules, which many older adults found difficult to manage.
Keep reading